Media OutReach – 1 December 2022 – ALR Technologies SG Ltd (“ALRT”) (OTCQB: ALRTF), the diabetes management company, today announced it has entered into a co-branded distribution agreement (the “Agreement”) with
Covetrus, Inc. (“Covetrus”), a global leader in animal-health technology and services, for ALRT’s
GluCurve Pet CGM, a continuous glucose monitoring (“CGM”) system for diabetic cats and dogs. The GluCurve Pet CGM is the first and only continuous glucose monitoring system designed for diabetic cats and dogs and sold directly to veterinarians.
“After meeting with many of the largest animal-health companies, Covetrus stood out as the clear choice as our partner to launch the GluCurve Pet CGM,” said Sidney Chan, chairman and CEO of ALRT. “Covetrus is uniquely suited for the sale and distribution of the GluCurve Pet CGM because of their industry leading service organization and differential go-to-market strategy that will help drive GluCurve to become the new standard of care for millions of diabetic animals around the world.”
According to studies1,2, 1 in 300 dogs and 1 in 175 cats have diabetes and until now, treating them could be a challenge for pet parents and veterinarians. The GluCurve records blood sugar levels every 3 minutes for up to 14 days, readings are displayed for the pet owner in the GluCurve app for iOS and Android and uploaded to a veterinary patient management web portal. In the web portal, the data are analyzed and organized into time saving graphs and tables, along with additional features such as glucose curve comparisons and overlays, insulin dose calculators, best practice guidelines, and more.
“We welcome the opportunity to bring innovative technologies and devices, such as the GluCurve Pet CGM, to market to help animal health professionals battle a progressive but often manageable disease such as diabetes, in new and innovative ways,” said Cesar França, president, Global Proprietary Brands at Covetrus. “Veterinarians and their patients are our first priority and bringing products and technology to our customers that improve access, reduce burden and enhance care are the cornerstones of our mission.”
Under the terms of the Agreement, Covetrus will have the exclusive rights to sell ALRT’s GluCurve Pet CGM as a co-branded product to veterinary clinics throughout the U.S., Brazil, United Kingdom, the European Union, and various other countries globally. Sales in the U.S. are expected to commence by the end of 2022.
The quantity of available units will ramp up monthly to support a full U.S. launch followed by a global launch as inventories permit.
1O’Neill, D G et al. “Epidemiology of Diabetes Mellitus among 193,435 Cats Attending Primary-Care Veterinary Practices in England.” Journal of veterinary internal medicine vol. 30,4 (2016): 964-72. doi:10.1111/jvim.14365
2Yoon, Samuel et al. “Epidemiological study of dogs with diabetes mellitus attending primary care veterinary clinics in Australia.” The Veterinary record vol. 187,3 (2020): e22. doi:10.1136/vr.105467
Hashtag: #petCGM #petdiabetes #vetmedicine #alrt
The issuer is solely responsible for the content of this announcement.